


DISCOVER THERAPEUTIC PLASMA EXCHANGE (TPE) POWERED BY THE PrisMax SYSTEM

TPE is a treatment for a number of hematological, neurological, renal and immunological diseases.¹ The American Society for Apheresis (ASFA) guidelines indicate that TPE is effective as first-line or second-line treatment for the following conditions:²



Renal Disorders

Goodpasture's syndrome

Neurological Disorders

- Guillain-Barré syndrome
- Myasthenia gravis

Hematologic Disorders

- Cryoglobulinemia
- Hyperviscosity in monoclonal gammopathies
- Thrombotic thrombocytopenic purpura (TTP)

The PrisMax system with TPE helps meet the demands for multiple critical care therapies

The **PrisMax** system was designed by Baxter to facilitate the delivery of not only TPE but also CRRT and HP. Building upon 20-plus years of critical care expertise, the **PrisMax** system aims to meet evolving needs of the ICU through enhanced simplicity, efficiency and accuracy of treatment delivery.

TPE therapy with the PrisMax system

- Designed to offer ease-of-use and simplicity from start to finish
- Provides enhanced safety features for greater confidence
- Designed to simplify workflows and to help drive operational efficiencies



The TPE therapy offering on PrisMax device expands your extracorporeal treatment options to large molecule removal and plasma exchange in your Intensive Care Unit^{*3}

Designed to offer ease-of-use and simplicity from start to finish

- Pre-connected sets and intuitive touchscreen interface
- Citrate capabilities and integrated syringe pump for heparin administration
- Scale stability software helps prevent false alarms caused by movement of bags or containers
- Advanced pressure management minimises alarms due to sudden pressure spikes caused by moving the patient

Provides enhanced safety features for greater confidence for the delivery of TPE


- Handheld barcode reader for auto-recognition of sets to limit human error
- · Self-regulating pressure system to automatically accommodate blood flow rate adjustments
- Ability to pre-fill the TPE circuit with blood before initiating treatment
- Small increments of flow rate to allow adjustment for lower body weight patients

Designed to simplify workflows and help drive operational efficiencies

- Setting up a TPE procedure on the **PrisMax** System is similar to setting up a CRRT treatment
- Hospitals that own a PrisMax System can run TPE therapy without the need for an additional device

Baxter offers two TPE sets for plasma protein removal in adults and children (>9kg)⁴

	TPE 2000 Set	TPE 1000 Set
Minimal Patient Weight	Adult	>9 kg
Effective surface area	0.35m ²	0.15m ²
Blood volume in plasmafilter	41 ml ±10%	22 ml ±10%
Blood volume in set	127 ml ±10%	73 ml ±10%
Minimum blood flow rate	100 ml/min	50 ml/min
Maximum blood flow rate	400 ml/min	180 ml/min
Filter membrane material	Polypropylene	



Plasma Filtration Rate (Q_F) capability and transmembrane pressure (TMP) with increased blood flow rate $(Q_B)^5$

Adequate plasma filtration rate can be achieved with small increases in TMP.

Sieving Coefficient (in		in vivo data – 19 treatments)'	
	Albumin	0.97	
	lgG	1.00	
	Apolipoprotein B	0.95	
	IgM	0.92	

Values are typical mean values obtained from laboratory testing of post-sterilisation sample lots. Results may vary depending on patient and clinical conditions.

For more information, please speak with a Baxter representative or visit www.baxter.com.

For safe and proper use of products mentioned herein, please refer to the appropriate Operators Manual or Instructions for Use.

1. Bambauer, R. (2013). Therapeutic Plasma Exchange and Selective Plasma Separation Methods. 4th Edition. Pabst Science Publishers. 2. Schwartz, et al. Guidelines on the Use of Therapeutic Apheresis in Clinical Practice-Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Seventh Special Issue. J Clin Apher. 2016;31:149-338. 3. Baxter - PrisMax Operators Manual. AW8005 Rev A. 2017; Sep. 4. Baxter - TPE 1000 and 2000, Instructions for Use. 2018; Jul. 5. Baxter - Data on file (DPM03127, 2003).

* Not all products and therapies are available in all countries

Baxter and PrisMax are trademarks of Baxter International Inc. or its subsidiaries NOR-AT26-230002 - August 2023

www.baxter.se Baxter Medical AB P 08 632 64 00 www.baxter.no Baxter AS P 22 58 48 00

www.baxter.fi Baxter Oy P (09) 8621 111 www.baxter.dk Baxter A/S P 4816 6400